2. Signaling Pathways
  3. Immunology/Inflammation
  4. Complement System

Complement System

Complement System

Related Products

PDF 0.66 MB

The complement system, composed of more than 30 serum and cell surface components, is collaborating in recognition and elimination of pathogens as a part of both the innate and acquired immune systems. Once the complement system is activated, a chain of reactions involving proteolysis and assembly occurs, resulting in cleavage of the third complement component (C3). The cascade up to C3 cleavage is called the activation pathway. There are three activation pathways: the classical, lectin, and alternative pathways.

The complement cascade is a dual-edged sword, causing protection against bacterial and viral invasion by promoting phagocytosis and inflammation. Pathologically, complement can cause substantial damage to blood vessels (vasculitis), kidney basement membrane and attached endothelial and epithelial cells (nephritis), joint synovium (arthritis), and erythrocytes (hemolysis) if it is not adequately controlled.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-N9481
    Lipoteichoic acid
    		Activator
    Lipoteichoic acid, a cell wall component of Staphylococcus aureus, activates the complement system via C3 induction and CD55 inhibition.
    Lipoteichoic acid
  • HY-P99520
    Vilobelimab
    		Inhibitor 99.27%
    Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc.
    Vilobelimab
  • HY-147297
    Pelecopan
    		Inhibitor 98.13%
    Pelecopan (BCX9930) is a potent, selective, orally active inhibitor of complement factor D with an IC50 value of 14.3 nM. Pelecopan can target factor D to prevent both intravascular and extravascular hemolysis in PNH. Pelecopan also be used for other alternative pathway (AP) mediated diseases.
    Pelecopan
  • HY-P99298
    Lampalizumab
    		Inhibitor 99.46%
    Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research.
    Lampalizumab
  • HY-P99450
    Avdoralimab
    		Inhibitor
    Avdoralimab (IPH 5401) is a fully human IgGκ monoclonal antibody that targets the complement C5a receptor 1 (C5aR1) that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research.
    Avdoralimab
  • HY-153098
    ARC186
    		Inhibitor
    ARC186, a aptamer, is highly potent complement inhibitors that function by blocking the convertase-catalyzed activation of C5.
    ARC186
  • HY-N7400
    Phaseoloidin
    		99.85%
    Phaseoloidin is a homogentisic acid glucoside from Nicotiana attenuata trichomes and contributes to the plant's resistance against lepidopteran herbivores. Phaseoloidin reduces larval growth of the specialist larvae Manduca sexta and the generalist larvae Spodoptera littoralis. Phaseoloidin has anti-complement activitie.
    Phaseoloidin
  • HY-P1505A
    C3a (70-77) (TFA)
    C3a (70-77) TFA (Complement 3a (70-77) TFA) is an octapeptide corresponding to the COOH terminus of C3a, exhibits the specificity and 1 to 2% biologic activities of C3a.
    C3a (70-77) (TFA)
  • HY-147762
    NRP1 antagonist 2
    		Antagonist 99.05%
    NRP1 antagonist 2 (Compound 1) is an NRP1 antagonist.
    NRP1 antagonist 2
  • HY-133034
    NRP1 antagonist 1
    		Antagonist 99.80%
    NRP1 antagonist 1 (compound 12a) is a potent NRP1 antagonist with an IC50 of 19.1 μM. NRP1 antagonist 1 has the potential for cancer research.
    NRP1 antagonist 1
  • HY-153785
    NH2-C6-ARC186 sodium
    		Inhibitor
    NH2-C6-ARC186 sodium is a modified ARC186 (HY-153098) with NH2-C6 that can be coupled to other peptides or molecules. ARC186 is a aptamer and a highly potent complement inhibitor that function by blocking the convertase-catalyzed activation of C5.
    NH2-C6-ARC186 sodium
  • HY-102034
    Complement factor D-IN-1
    		98.85%
    Complement factor D-IN-1 is a potent and selective small-molecule reversible factor d inhibitor, with IC50s of 0.006 and 0.05 μM in FD Thioesterolytic Fluorescent Assay and a MAC Deposition Assay, respectively.
    Complement factor D-IN-1
  • HY-P99638
    Gefurulimab
    		Inhibitor
    Gefurulimab (ALXN-1720) is a human-derived bispecific antibody against complement C5 and albumin that binds C5 and blocks its activation.
    Gefurulimab
  • HY-15701A
    (Z)-Leukadherin-1
    		Agonist ≥98.0%
    (Z)-Leukadherin-1 (ADH-503 free base) is an orally active and allosteric CD11b agonist. (Z)-Leukadherin-1 leads to the repolarization of tumor-associated macrophages, reduction in the number of tumor-infiltrating immunosuppressive myeloid cells, and enhances dendritic cell responses.
    (Z)-Leukadherin-1
  • HY-P99965
    Crovalimab
    		Inhibitor 98.61%
    Crovalimab (SKY59; RO7112689) is a novel humanized antibody against C5 in a pH-dependent manner with KDs of 15.2 nM and 16.8 μM at pH 7.4 and 5.8, respectively. Crovalimab binds human FcRn with great affinity (KD: 17 μM at pH 6.0). Crovalimab can block cleavage of C5 by the C5 convertase and inhibite the activity of a C5 variant (p.Arg885His). Crovalimab inhibits C5b-9 formation significantly in all three complement pathways, the classical pathway (CP), lectin pathway (LP), and alternative pathway (AP). Crovalimab has the potential for paroxysmal nocturnal hemoglobinuria (PNH) and complement-mediated diseases research.
    Crovalimab
  • HY-14648S
    Dexamethasone-d5
    		Inhibitor 99.86%
    Dexamethasone-d5 is the deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses[1][2].
    Dexamethasone-d<sub>5</sub>
  • HY-136556
    Factor B-IN-1
    		Inhibitor
    Factor B-IN-1 is a Factor B inhibitor extracted from patent WO2013164802A1, Example 24.
    Factor B-IN-1
  • HY-P990091
    Riliprubart
    		Inhibitor 99.90%
    Riliprubart (SAR445088) is an anti-C1s humanized monoclonal antibody that inhibits activated C1s in the proximal portion of the classical complement system. Riliprubart selectively inhibits activated C1s and prevents the enzymatic action of C1 on its substrates C4 and C2, thus inhibiting the formation of the classical pathway C3 convertase, C4b2a.
    Riliprubart
  • HY-B0579S
    Cyclosporin A-d4
    		99.20%
    Cyclosporin A-d4 is the deuterium labeled Cyclosporin A. Cyclosporin A (Cyclosporine A) is an immunosuppressant which binds to the cyclophilin and inhibits phosphatase activity of calcineurin with an IC50 of 5 nM. Cyclosporin A also inhibits CD11a/CD18 ad
    Cyclosporin A-d<sub>4</sub>
  • HY-P99786
    Pozelimab
    		Inhibitor 99.45%
    Pozelimab (REGN3918) is a fully human IgG4 anti-C5 monoclonal antibody. Pozelimab binds to C5 and C5 variants with high affinity and blocks complement-mediated hemolysis. Pozelimab can be used for the research of complement-mediated diseases.
    Pozelimab
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity